NASDAQ OMX

Sunshine Heart Announces Closing of $9.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

24.4.2017 19:03 | NASDAQ OMX

Dela

EDEN PRAIRIE, Minn., April 24, 2017 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today the closing of an underwritten public offering of units for gross proceeds of $9.2 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Sunshine Heart.

The offering comprised of Class A Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock and one five-year warrant (each, a "warrant") to purchase one share of common stock with an exercise price of $1.10 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock, which is convertible into 1,000 shares of common stock, and warrants to purchase 1,000 shares of common stock, also with an exercise price of $1.10 per share. The conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed priced and do not contain any variable pricing features nor any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock), liquidation preference or other preferences over common stock. The securities comprising the units are immediately separable and will be issued separately.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., acted as sole book-running manager in connection with the offering.

A total of 2.8 million shares of common stock, 6,400 shares of preferred stock convertible into 6.4 million shares of common stock, and warrants to purchase 9.2 million shares of common stock were issued in the offering.

The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-216841), which was declared effective by the United States Securities and Exchange Commission ("SEC") on April 18, 2017.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to this offering was filed by Sunshine Heart with the SEC. Copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172, by calling (212) 409-2000.

About Sunshine Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow® System. The Company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Our objective is to improve the quality of life for patients with heart failure and related conditions. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, our ability to execute on our recently announced strategic realignment, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses. The risk factors described in our filings with the SEC could cause actual events to adversely differ from the expectations indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sunshine Heart does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Sunshine Heart may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our therapy, the possibility we may be unable to raise the funds necessary for the development and commercialization of our therapy and other risks and uncertainties described in our filings with the SEC. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

For further information, please contact: 

Claudia Napal Drayton
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4205

Investor Relations
Sunshine Heart Inc.
ir@sunshineheart.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sunshine Heart, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

TGS and PGS Announce Fourth 3D Seismic Project Offshore Eastern Canada26.5.2017 07:50

ASKER, Norway, May 26, 2017 (GLOBE NEWSWIRE) -- TGS and Petroleum Geo-Services ("PGS") announce the fourth 3D seismic project offshore Eastern Canada for 2017. Long Range 3D will comprise approximately 9,100 km2 of 3D GeoStreamer® data in the Eastern Newfoundland region. The survey covers open acreage which will be included in the November 2018 licensing round under Newfoundland and Labrador's Scheduled Land Tenure system. Following completion of these surveys, the jointly-owned library will have more than 175,000 km of 2D GeoStreamer data and 28,500 km2 of 3D GeoStreamer data. An expansive well log library is also available in the region, along with advanced multi-client interpretation products that will improve play, trend and prospect delineation. "With four 3D projects now committed for 2017 this will be our most active year ever in Newfoundland and Labrador. E&P companies are continuing to prioritize this region in their exploration strat

Mandalay Resources Corporation går ut med slutförande av reviderat Återköpserbjudande och begäran om medgivande gällande 5,875 % säkerställda utbytbara skuldebrev25.5.2017 13:46

TORONTO 24 maj 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" eller "Bolaget") (TSX:MND) meddelade idag att Gold Exchange Limited ("GEL"), ett självständigt företag för särskilda ändamål som är registrerat i Jersey, har ingått avtal gällande ett reviderat återköpserbjudande ("Återköpet") och en begäran om medgivande ("Begäran om medgivande") för sitt kapitalbelopp på 60 000 000 USD, 5,875 % säkerställda utbytbara skuldebrev som löper ut 2019 ("Skuldebreven"). GEL gav ut Skuldebreven 2014 och lånade ut inkomsterna till ett av Bolagets dotterbolag i enlighet med villkoren för låneavtalet och relaterad finansieringsöverenskommelse ("Lånet") som tillsammans speglar de huvudsakliga villkoren för Skuldebreven. Som angivet i Mandalays pressmeddelande från den 12 maj 2017, slutfördes inte det ursprungliga återköpserbjudandet och begäran om medgivande som GEL lanserade gällande Skuldebreven

Karolinska Development's Annual General Meeting 201724.5.2017 20:00

STOCKHOLM - May 24, 2017. At the Annual General Meeting of Karolinska Development AB held May 24, 2017, the following resolutions were passed: Profit and loss statement and the balance sheet: It was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet. Appropriation of the company's result: It was resolved to approve the allocation of the result, proposed by the board and the CEO, in total SEK -12 406 768 be allocated as follows: To be carried forward SEK -12 406 768. Discharge from liability of the directors and the CEO: It was resolved to grant the directors and the CEO discharge from liability for the financial year 2016. Resolution regarding the number of directors and auditors and deputy auditors to be appointed: It was resolved that the number of directors shall be seven without deputies and that the number

Karolinska Developments årsstämma 201724.5.2017 20:00

STOCKHOLM den 24 maj 2017. Vid Karolinska Developments årsstämma som hölls den 24 maj 2017 beslutade aktieägarna, följande: Redovisning: beslutades att fastställa av resultaträkning och balansräkning samt koncernresultaträkning och koncernbalansräkning. Resultatdisposition:  beslöts att godkänna styrelsens och verkställande direktörens förslag att till årsstämmans förfogande stående medel, sammanlagt SEK -12 406 768, disponeras enligt följande: SEK -12 406 768 balanseras i ny räkning. Ansvarsfrihet för styrelsens ledamöter och VD: beslöts att bevilja styrelsen och verkställande direktören ansvarsfrihet för verksamhetsåret 2016. Fastställande av antalet styrelseledamöter samt revisorer och revisorssuppleanter: Beslöts att antalet ledamöter i styrelsen skall vara sju utan suppleanter samt att antalet revisorer skall vara en utan suppleanter. Fastställande av arvoden till styrelsen och revisorerna: bes

Nasdaq to Deliver Post-Trade Technology to Depósito Central de Valores (DCV)24.5.2017 15:00

The Chilean central securities depository (CSD) will boost its infrastructure capabilities and increase efficiencies with fully-fledged CSD solution based on the Nasdaq Financial Framework NEW YORK and SANTIAGO, Chile, May 24, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) and Depósito Central de Valores (DCV)  today announced a new landmark agreement to bolster the technological infrastructure of Chile's central securities depository (CSD). "We are very satisfied with our thorough, year-long vendor partnership process in selecting the Nasdaq platform, which will replace the core system of the DCV," said Fernando Yáñez, CEO of DCV. "We believe with the implementation of this new system, we will have more opportunities for growth and diversification in our current services, as well as strengthening our day-to-day operations." Under the agreement with DCV, Nasdaq will deliver its CSD Solution, which will allow for:

Mandalay Resources Corporation Announces Completion of Revised Repurchase Offer and Consent Solicitation in Respect of 5.875% Secured Exchangeable Bonds24.5.2017 14:11

TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) announced today that Gold Exchange Limited ("GEL"), an unaffiliated special purpose vehicle incorporated in Jersey, has entered into agreements with respect to a revised repurchase offer (the "Repurchase") and consent solicitation (the "Consent Solicitation") in respect of its U.S.$60,000,000 principal amount 5.875% secured exchangeable bonds due 2019 (the "Bonds"). GEL issued the Bonds in 2014 and loaned the proceeds to a subsidiary of the Company pursuant to the terms of a loan agreement and related funding agreement (the "Loan") which together mirror the principal terms of the Bonds. As indicated in Mandalay's press release of May 12, 2017, the original repurchase offer and consent solicitation that GEL launched in respect of the Bonds on April 19, 2017 (the "Original Proposed

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum